SMARCA4 biology in alveolar rhabdomyosarcoma

Narendra Bharathy; Megan M. Cleary; Jin Ah Kim; Kiyo Nagamori; Kenneth A. Crawford; Eric Wang; Debarya Saha; Teagan P. Settelmeyer; Reshma Purohit; Damianos Skopelitis; Kenneth Chang; Jessica A. Doran; C. Ward Kirschbaum; Suriya Bharathy; Davis W. Crews; Matthew E. Randolph; Anthony N. Karnezis; Lisa Hudson-Price; Jyotsna Dhawan; Joel E. Michalek; Alessio Ciulli; Christopher R. Vakoc; Charles Keller

doi:10.1038/s41388-022-02205-0

SMARCA4 biology in alveolar rhabdomyosarcoma

Narendra Bharathy, Megan M. Cleary, Jin Ah Kim, Kiyo Nagamori, Kenneth A. Crawford, Eric Wang, Debarya Saha, Teagan P. Settelmeyer, Reshma Purohit, Damianos Skopelitis, Kenneth Chang, Jessica A. Doran, C. Ward Kirschbaum, Suriya Bharathy, Davis W. Crews, Matthew E. Randolph, Anthony N. Karnezis, Lisa Hudson-Price, Jyotsna Dhawan, Joel E. MichalekAlessio Ciulli, Christopher R. Vakoc, Charles Keller

Department of Population Health Sciences

Producción científica: Article › revisión exhaustiva

10 Citas (Scopus)

Resumen

Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children and phenocopies a muscle precursor that fails to undergo terminal differentiation. The alveolar subtype (ARMS) has the poorest prognosis and represents the greatest unmet medical need for RMS. Emerging evidence supports the role of epigenetic dysregulation in RMS. Here we show that SMARCA4/BRG1, an ATP-dependent chromatin remodeling enzyme of the SWI/SNF complex, is prominently expressed in primary tumors from ARMS patients and cell cultures. Our validation studies for a CRISPR screen of 400 epigenetic targets identified SMARCA4 as a unique factor for long-term (but not short-term) tumor cell survival in ARMS. A SMARCA4/SMARCA2 protein degrader (ACBI-1) demonstrated similar long-term tumor cell dependence in vitro and in vivo. These results credential SMARCA4 as a tumor cell dependency factor and a therapeutic target in ARMS.

Idioma original	English (US)
Páginas (desde-hasta)	1647-1656
Número de páginas	10
Publicación	Oncogene
Volumen	41
N.º	11
DOI	https://doi.org/10.1038/s41388-022-02205-0
Estado	Published - mar 10 2022

ASJC Scopus subject areas

Genetics
Molecular Biology
Cancer Research

Acceder al documento

10.1038/s41388-022-02205-0

Otros archivos y enlaces

Citar esto

Bharathy, N., Cleary, M. M., Kim, J. A., Nagamori, K., Crawford, K. A., Wang, E., Saha, D., Settelmeyer, T. P., Purohit, R., Skopelitis, D., Chang, K., Doran, J. A., Kirschbaum, C. W., Bharathy, S., Crews, D. W., Randolph, M. E., Karnezis, A. N., Hudson-Price, L., Dhawan, J., ... Keller, C. (2022). SMARCA4 biology in alveolar rhabdomyosarcoma. Oncogene, 41(11), 1647-1656. https://doi.org/10.1038/s41388-022-02205-0

Bharathy, N, Cleary, MM, Kim, JA, Nagamori, K, Crawford, KA, Wang, E, Saha, D, Settelmeyer, TP, Purohit, R, Skopelitis, D, Chang, K, Doran, JA, Kirschbaum, CW, Bharathy, S, Crews, DW, Randolph, ME, Karnezis, AN, Hudson-Price, L, Dhawan, J, Michalek, JE, Ciulli, A, Vakoc, CR & Keller, C 2022, 'SMARCA4 biology in alveolar rhabdomyosarcoma', Oncogene, vol. 41, n.º 11, pp. 1647-1656. https://doi.org/10.1038/s41388-022-02205-0

@article{77cabaf3ace84afe97d4504e3dd089d8,

title = "SMARCA4 biology in alveolar rhabdomyosarcoma",

abstract = "Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children and phenocopies a muscle precursor that fails to undergo terminal differentiation. The alveolar subtype (ARMS) has the poorest prognosis and represents the greatest unmet medical need for RMS. Emerging evidence supports the role of epigenetic dysregulation in RMS. Here we show that SMARCA4/BRG1, an ATP-dependent chromatin remodeling enzyme of the SWI/SNF complex, is prominently expressed in primary tumors from ARMS patients and cell cultures. Our validation studies for a CRISPR screen of 400 epigenetic targets identified SMARCA4 as a unique factor for long-term (but not short-term) tumor cell survival in ARMS. A SMARCA4/SMARCA2 protein degrader (ACBI-1) demonstrated similar long-term tumor cell dependence in vitro and in vivo. These results credential SMARCA4 as a tumor cell dependency factor and a therapeutic target in ARMS.",

author = "Narendra Bharathy and Cleary, {Megan M.} and Kim, {Jin Ah} and Kiyo Nagamori and Crawford, {Kenneth A.} and Eric Wang and Debarya Saha and Settelmeyer, {Teagan P.} and Reshma Purohit and Damianos Skopelitis and Kenneth Chang and Doran, {Jessica A.} and Kirschbaum, {C. Ward} and Suriya Bharathy and Crews, {Davis W.} and Randolph, {Matthew E.} and Karnezis, {Anthony N.} and Lisa Hudson-Price and Jyotsna Dhawan and Michalek, {Joel E.} and Alessio Ciulli and Vakoc, {Christopher R.} and Charles Keller",

note = "Publisher Copyright: {\textcopyright} 2022, The Author(s), under exclusive licence to Springer Nature Limited.",

year = "2022",

month = mar,

day = "10",

doi = "10.1038/s41388-022-02205-0",

language = "English (US)",

volume = "41",

pages = "1647--1656",

journal = "Oncogene",

issn = "0950-9232",

publisher = "Springer Nature",

number = "11",

}

TY - JOUR

T1 - SMARCA4 biology in alveolar rhabdomyosarcoma

AU - Bharathy, Narendra

AU - Cleary, Megan M.

AU - Kim, Jin Ah

AU - Nagamori, Kiyo

AU - Crawford, Kenneth A.

AU - Wang, Eric

AU - Saha, Debarya

AU - Settelmeyer, Teagan P.

AU - Purohit, Reshma

AU - Skopelitis, Damianos

AU - Chang, Kenneth

AU - Doran, Jessica A.

AU - Kirschbaum, C. Ward

AU - Bharathy, Suriya

AU - Crews, Davis W.

AU - Randolph, Matthew E.

AU - Karnezis, Anthony N.

AU - Hudson-Price, Lisa

AU - Dhawan, Jyotsna

AU - Michalek, Joel E.

AU - Ciulli, Alessio

AU - Vakoc, Christopher R.

AU - Keller, Charles

PY - 2022/3/10

Y1 - 2022/3/10

N2 - Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children and phenocopies a muscle precursor that fails to undergo terminal differentiation. The alveolar subtype (ARMS) has the poorest prognosis and represents the greatest unmet medical need for RMS. Emerging evidence supports the role of epigenetic dysregulation in RMS. Here we show that SMARCA4/BRG1, an ATP-dependent chromatin remodeling enzyme of the SWI/SNF complex, is prominently expressed in primary tumors from ARMS patients and cell cultures. Our validation studies for a CRISPR screen of 400 epigenetic targets identified SMARCA4 as a unique factor for long-term (but not short-term) tumor cell survival in ARMS. A SMARCA4/SMARCA2 protein degrader (ACBI-1) demonstrated similar long-term tumor cell dependence in vitro and in vivo. These results credential SMARCA4 as a tumor cell dependency factor and a therapeutic target in ARMS.

AB - Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children and phenocopies a muscle precursor that fails to undergo terminal differentiation. The alveolar subtype (ARMS) has the poorest prognosis and represents the greatest unmet medical need for RMS. Emerging evidence supports the role of epigenetic dysregulation in RMS. Here we show that SMARCA4/BRG1, an ATP-dependent chromatin remodeling enzyme of the SWI/SNF complex, is prominently expressed in primary tumors from ARMS patients and cell cultures. Our validation studies for a CRISPR screen of 400 epigenetic targets identified SMARCA4 as a unique factor for long-term (but not short-term) tumor cell survival in ARMS. A SMARCA4/SMARCA2 protein degrader (ACBI-1) demonstrated similar long-term tumor cell dependence in vitro and in vivo. These results credential SMARCA4 as a tumor cell dependency factor and a therapeutic target in ARMS.

UR - http://www.scopus.com/inward/record.url?scp=85123827905&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85123827905&partnerID=8YFLogxK

U2 - 10.1038/s41388-022-02205-0

DO - 10.1038/s41388-022-02205-0

M3 - Article

C2 - 35094009

AN - SCOPUS:85123827905

SN - 0950-9232

VL - 41

SP - 1647

EP - 1656

JO - Oncogene

JF - Oncogene

IS - 11

ER -

SMARCA4 biology in alveolar rhabdomyosarcoma

Resumen

ASJC Scopus subject areas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto